Open access chemical and clinical probes to support drug discovery
- 1 July 2009
- journal article
- Published by Springer Nature in Nature Chemical Biology
- Vol. 5 (7) , 436-440
- https://doi.org/10.1038/nchembio0709-436
Abstract
Drug discovery resources in academia and industry are not used efficiently, to the detriment of industry and society. Duplication could be reduced, and productivity could be increased, by performing basic biology and clinical proofs of concept within open access industry-academia partnerships. Chemical biologists could play a central role in this effort.Keywords
This publication has 23 references indexed in Scilit:
- Large-Scale Structural Biology of the Human ProteomeAnnual Review of Biochemistry, 2009
- Small molecules and chemical tools at the interfaceNature Chemical Biology, 2008
- Structural genomics and drug discovery: all in the familyCurrent Opinion in Chemical Biology, 2008
- Advances in the design and therapeutic use of capsaicin receptor TRPV1 agonists and antagonistsExpert Opinion on Therapeutic Patents, 2008
- MMPs as therapeutic targets—Still a viable option?Published by Elsevier ,2007
- Inhibition of Hyperalgesia by Ablation of Lamina I Spinal Neurons Expressing the Substance P ReceptorScience, 1997
- Pain, Tenderness, Wheal and Flare Induced by Substance-P, Bradykinin and 5-Hydroxytryptamine in HumansCephalalgia, 1991
- Substance p and arthritis: analysis of plasma and synovial fluid levelsArthritis & Rheumatism, 1990
- Algesia and local responses induced by neurokinin A and substance P in human skin and temporal musclePeptides, 1989
- Staurosporine, a potent inhibitor of phospholipidCa++dependent protein kinaseBiochemical and Biophysical Research Communications, 1986